{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:59:51Z","timestamp":1788951591140,"version":"build-2803163510"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post\u2010ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression\u2010free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post\u2010ASCT BV maintenance in the real\u2010life setting of 23 Italian hematology centers. This population included na\u00efve patients and those previously exposed to BV. Median follow\u2010up was 20 months. Patients presented a median of two lines of treatment pre\u2010ASCT, with 51% receiving BV. Twenty\u2010nine percent of patients had at least two high\u2010risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET\u2010CT, a Deauville score (DS) of 1\u20133 was reported in 75% and 78% of pre\u2010 and post\u2010ASCT evaluations, respectively. Grade 3\u20134 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three\u2010year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3\u2010year PFS and OS were 54% and 71%, respectively, for na\u00efve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.003) and post\u2010ASCT DS 4\u20135 (HR 3.14;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post\u2010ASCT BV maintenance is an effective, safe treatment option for cHL na\u00efve patients and those previously exposed to BV.\n                  <\/jats:p>","DOI":"10.1002\/hon.2939","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T10:59:56Z","timestamp":1635159596000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real\u2010life experience"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-7957","authenticated-orcid":false,"given":"Fulvio","family":"Massaro","sequence":"first","affiliation":[{"name":"PhD Program in Clinical and Experimental Medicine University of Modena and Reggio Emilia  Modena Italy"},{"name":"Hematology Unit Azienda Unit\u00e0 Sanitaria Locale\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico  Tricase Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero Maria","family":"Stefani","sequence":"additional","affiliation":[{"name":"Hematology Unit General Hospital Ca' Foncello  Treviso Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Division of Hematology Citt\u00e0 della Salute e della Scienza Hospital and University  Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine Sapienza University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"Division of Onco\u2010Hematology Azienda Villa Sofia\u2010Cervello  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[{"name":"Unit of Lymphoproliferative Disorders Policlinico Tor Vergata  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit Department of Medicine (DIMED) University of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Potito Rosario","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Department of Hematology Casa Sollievo della Sofferenza  San Giovanni Rotondo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[{"name":"Hematology Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII  Bergamo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Division of Hematology Department of Clinical and Experimental Medicine University of Pisa  Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cimminiello","sequence":"additional","affiliation":[{"name":"Hematology San Carlo Hospital  Potenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[{"name":"Division of Hematology Azienda Ospedaliera Universitaria Ospedali Riuniti  Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[{"name":"Department of Oncology Hematology and BMT Unit Casa di Cura La Maddalena  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sorio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine Hematology and Bone Marrow Transplant Unit University of Verona  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Arcari","sequence":"additional","affiliation":[{"name":"Hematology Unit Ospedale Guglielmo da Saliceto  Piacenza Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[{"name":"Division of Hematology ASST Grande Ospedale Metropolitano Niguarda  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[{"name":"Unit of Haematology Azienda Ospedaliera Papardo  Messina Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Hematology Azienda Ospedaliero\u2010Universitaria Senese  Siena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pietrantuono","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata  Rionero in Vulture Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-5313","authenticated-orcid":false,"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[{"name":"Unit of Haematology and Stem Cell Transplantation Campus Bio\u2010Medico University  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tafuri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine and Hematology Sant\u2019Andrea \u2013 University Hospital \u2013 Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Prete","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico  Tricase Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mul\u00e8","sequence":"additional","affiliation":[{"name":"Division of Onco\u2010Hematology Azienda Villa Sofia\u2010Cervello  Palermo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbolini","sequence":"additional","affiliation":[{"name":"Gruppo Amici dell'Ematologia GRADE\u2010Onlus Foundation  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Linfomi Onlus  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luminari","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Unit\u00e0 Sanitaria Locale\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[{"name":"Hematology Unit Azienda Unit\u00e0 Sanitaria Locale\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000067"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4817"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08616.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.06.006"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.018"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388058"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5771"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704661"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood.V122.21.4648.4648","article-title":"A phase III randomized, double blind, placebo controlled multi\u2010center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation","volume":"122","author":"Von Tresckow B","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138666"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2897"},{"issue":"1","key":"e_1_2_8_20_1","first-page":"2806","article-title":"Radiographic and high throughput sequencing (HTS)\u2010based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (rel\/ref) classical Hodgkin lymphoma (cHL): updated results of a phase I\/II trial","volume":"130","author":"Cassaday RD","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1109.1109"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196899"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-815183"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2939","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:24:19Z","timestamp":1692991459000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/hon.2939"],"URL":"https:\/\/doi.org\/10.1002\/hon.2939","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2939\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2939\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2939\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2939\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2939\/v1\/review2","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2021-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}